Table 3 Complete pathological response rate (%pCR) with univariable logistic regression analysis predicting for pCR and %6-year event-free survival (EFS) rate in the NeoALTTO trial with univariable Cox regression analysis predicting for EFS based on treatment arms and adaptive immune-signature status (high vs. low).

From: Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Treatment arms

%pCR AIS low (N = 134)

%pCR AIS high (N = 110)

ORa (95%CI, p value)

%6-yr EFS AIS low (95%CI)

%6-yr EFS AIS high (95%CI)

HRb (95%CI, p value)

Arm 1: lapatinib

15.2% (7)

23.1% (9)

1.67 (0.56–5.17, 0.358)

71.5% (58.5–87.5%)

62.3% (47.9–81.1%)

1.35 (0.61–2.98, 0.457)

Arm 2: trastuzumab

9.8% (4)

41.7% (15)

6.61 (2.09–25.59, 0.003)

60.8% (47.1–78.5%)

76.2% (63.1–92.1%)

0.59 (0.25–1.39, 0.226)

Arm 3: combination of trastuzumab and lapatinib

51.1% (24)

45.7% (16)

0.81 (0.33–1.94, 0.632)

76.1% (64.2–90.24%)

81.1% (68.5–96.01%)

0.85 (0.32–2.24, 0.741)

  1. aThe outcome was modeled with pCR using the Logistic regression model.
  2. bThe outcome was modeled with the composite endpoint of progression, relapse, or death using the Cox regression model.
Back to article page